New Drugs for Management of Diabetes: Insulin Analogues, Inhaled Insulin, Pramlintide, and Novel Peptides
| Autor: | Jay F. Mouser |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Type 1 diabetes Nutrition and Dietetics business.industry Insulin medicine.medical_treatment Medicine (miscellaneous) Type 2 diabetes Hypoglycemia medicine.disease Bioinformatics Pramlintide Endocrinology Basal (medicine) Internal medicine Diabetes mellitus medicine business Glycemic medicine.drug |
| Zdroj: | Nutrition in Clinical Practice. 19:172-180 |
| ISSN: | 1941-2452 0884-5336 |
| DOI: | 10.1177/0115426504019002172 |
| Popis: | Diabetes mellitus has reached epidemic proportions and contributes to considerable morbidity and mortality in the form of metabolic, microvascular, and macrovascular complications. Although there is no cure, large controlled studies demonstrate the importance of strict glycemic control in reducing progression of microvascular disease and associated morbidity. Insulin replacement is necessary for all patients with type 1 diabetes. In treatment of type 2 diabetes, more timely addition of insulin as patients fail to attain glycemic targets on combinations of oral agents has become widely accepted.Pharmacokinetic properties of human insulins limit their ability to mimic physiologic insulin secretion. Analog insulins (prandial and basal) are designed with improved physiologic pharmacokinetic characteristics to enable more simplified insulin dosage adjustments and a reduced risk for hypoglycemia. Inhaled administration has emerged as a promising route for noninvasive prandial insulin. Clinical trials are under ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text